Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07066735
Starting soon Not applicable

Extracorporeal Shock-Wave Therapy (ESWT) vs Phytotherapy vs Combined in Treatment of Chronic Prostatitis

NCT07066735 · tracked via the Priya Life Science Egypt tracker
Sponsor
Ain Shams University
Phase
Not applicable
Started
2025-07-20
Last updated
2025-07-17

Condition(s) studied

Chronic Prostatitis (CP)

Investigational drug(s) / intervention(s)

ESWTPhytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin

ESWT: Transperineal Shockwaves that are applied once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)

Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin: 1capsule tob be taken twice daily for one month.

Study summary

to compare the efficacy and safety of ESWT combined with phytotherapy, ESWT alone and phytotherapy alone in treatment of chronic prostatitis.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Perineal or pelvic pain or discomfort of at least 3 months * NIH-CPSI total score greater than 15, * Negative semen cultures for bacteria. Exclusion Criteria: * Evidence of bacteria in seminal culture tests, * Urinary stones, * Uncontrolled coagulopathy, * Chronic bacterial prostatitis, * Bladder and prostate cancer, * Medications that could affect lower urinary tract function during the last month * Serum prostate-specific antigen levels (PSA) more than 4 ng/mL * History of prostate surgery or radiotherapy * Perineal anatomical abnormalities * Neurological abnormalities. * Previous extensive pelvic injuries

Primary outcome measure(s)

  • compare the degree of symptoms relief between the three groups — pre intervenon, at 4 and 8 weeks post intervention and at 2 and 4 months post intervention.
    using National Institutes of Health-developed Chronic Prostatitis Symptom Index (NIHCPSI) that will be filled by the patients pre and post intervention at 4 weeks and 8 weeks, 2 and 4 months. It comprises three key domains: pain (scored from 0 to 21), urinary symptoms (0 to 10), and the impact on quality of life (0 to 12), with a total score range spanning from 0 to 43. Higher scores reflect more severe symptoms and a worse overall outcome, while lower scores indicate milder symptoms and a better clinical picture. Severity is typically interpreted as mild (0-9), moderate (10-18), severe (19-31), and very severe (32-43), making the scale valuable for both diagnosis and monitoring treatment progress.

Trial sites (1)

FacilityCityRegionStatus
AinShams University hospitals Cairo Egypt

More Ain Shams University trials in Egypt

Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure Recruiting
3D Analysis of Soft Tissue Healing After Immediate Implant Placement Using PRF Vs HAM Active, not recruiting
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival Recruiting
Efficacy of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block for Postoperative Pain Control Following Video-assisted Thoracoscopic Surgeries (VATS): Randomized Control Trial Recruiting
Effect of Kangaroo Mother Care on Energy Utilization in Preterm Neonates Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07066735 on ClinicalTrials.gov ↗ ← All trials in Egypt